ACET — Adicet Bio, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1720580 ·
Last close
$8.33
Market Cap
$77.87M
52W High
$8.90
52W Low
$6.01
ADV30
122,868
Next earnings
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -21,570,000 -20,244,000 169,382,000 36,245,000 29,317,000
Dec 2025 0 -31,886,000 -30,516,000 192,355,000 38,918,000 33,145,000
Sep 2025 0 -27,952,000 -26,856,000 140,479,000 29,099,000 31,337,000
Jun 2025 0 -32,392,000 -31,217,000 162,972,000 34,720,000 29,600,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-95,246,000
Investing CF
$2,393,000
Financing CF
$75,245,000
CapEx
$-1,924,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-17.98
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-614,697,000
Inventory
Receivables
$342,000
ST Investments
$119,612,000
EBIT TTM
$-116,767,000
Pretax Income TTM
$-116,803,000
Interest Exp TTM
$36,000
Analysts
6

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -122,114,000 -116,803,000 192,355,000 33,145,000 -95,246,000
Dec 2024 0 -127,615,000 -117,122,000 220,219,000 33,610,000 -92,378,000
Dec 2023 0 -132,576,000 -142,658,000 207,295,000 37,120,000 -93,717,000
Dec 2022 24,990,000 -72,551,000 -69,790,000 330,690,000 38,352,000 -44,765,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-4.19

Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)

max pain strike: $7.50 · spot: $8.33 · call volume: 310 · put volume: 21
Expected Move to 2026-07-17: ±$3.83 (45.98%) — implied range $4.50$12.16 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RLYB Rallybio Corp $77.88M $14.70
OSTX OS Therapies Inc $77.94M $1.75
GANX Gain Therapeutics, Inc. $77.63M $1.82
PLRX PLIANT THERAPEUTICS, INC. $76.78M $1.24
HYFT MindWalk Holdings Corp. $76.14M $1.63

News headlines (Yahoo Finance, 1h cache)

Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade
2026-05-25 13:55 · Yahoo
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
2026-05-14 20:00 · Yahoo
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-13 20:01 · Yahoo
Adicet Bio (ACET) Upgraded to Buy: Here's Why
2026-03-24 16:00 · Yahoo
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
2026-03-12 20:00 · Yahoo
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
2026-01-30 12:00 · Yahoo
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
2026-01-07 12:00 · Yahoo
Adicet Bio Announces Reverse Stock Split
2025-12-26 13:30 · Yahoo
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2025-11-28 19:23 · Yahoo
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
2025-11-12 21:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.